Small Cell Lung Cancer Therapeutics Global Market Report 2024

The global small cell lung cancer therapeutics market has grown rapidly in recent years. It will grow from $5.78 billion in 2023 to $6.62 billion in 2024 at a compound annual growth rate (CAGR) of 14.6%. The growth in the historic period can be attributed to increasing prevalence of small cell lung cancer, growing awareness about small cell lung cancer, growing demand for effective and convenient treatments, government initiatives.

The global small cell lung cancer therapeutics market is expected to see rapid growth in the next few years. It will grow to $10.87 billion in 2028 at a compound annual growth rate (CAGR) of 13.2%. The growth in the forecast period can be attributed to investments in research and development activities for small cell lung cancer treatments, rising toboco smoking, growing chemotherapy, increasing healthcare expenditure. Major trends in the forecast period include advances in early detection and screening methods, clinical trial expansion, advances in radiation therapy, immunotherapy advancements.

The increasing incidence of lung cancer is poised to be a significant driver of the future expansion in the small-cell lung cancer therapeutics market. Lung cancer is a malignant disease characterized by symptoms like coughing, chest pain, and breathing difficulties, resulting from the uncontrolled proliferation of abnormal cells within the lung tissues. The treatment of lung cancer, including small-cell lung cancer, typically encompasses a combination of chemotherapy, radiation therapy, and, in certain cases, targeted therapies. These treatment modalities aim to provide extended survival and an improved quality of life for individuals dealing with lung cancer.For example, in January 2023, as reported by the American Cancer Society, a government organization based in the United States, there were approximately 238,340 new cases of lung cancer (117,550 in men and 120,790 in women) in 2022. Furthermore, there were reportedly 127,070 deaths resulting from lung cancer (67,160 in men and 59,910 in women) during the same year. Hence, the escalating prevalence of lung cancer stands as a driving force behind the growth of the small-cell lung cancer therapeutics market.

The burgeoning prevalence of tobacco use is expected to be a driving force behind the expansion of the small-cell lung cancer (SCLC) therapeutics market in the near future. Several factors contribute to the increased use of tobacco, including population growth, marketing and advertising, insufficient regulation, social and cultural influences, stress as a coping mechanism, the addictive properties of nicotine, and the ready availability of tobacco products. Tobacco smoke contains a multitude of carcinogenic compounds, such as polycyclic aromatic hydrocarbons (PAHs) and nitrosamines. When individuals inhale these substances, they have the potential to damage the DNA within lung cells, causing mutations that can trigger the development of cancer, including SCLC.For instance, in July 2022, as reported by Statistics Canada, a government agency based in Canada, cigarette production witnessed a 5.8% increase compared to June 2021. Additionally, the total number of cigarettes sold rose by 1.3% from May 2022, reaching 1.4 billion in June 2022. Furthermore, in May 2023, data from the Centers for Disease Control and Prevention, a government agency in the United States, indicated that an estimated 28.3 million U.S. adults are cigarette smokers, and approximately 3.08 million U.S. middle and high school students use at least one tobacco product. Alarmingly, around 1,600 U.S. youth under the age of 18 start smoking their first cigarette on a daily basis. Consequently, the rising prevalence of tobacco use serves as a pivotal driver propelling the small-cell lung cancer (SCLC) therapeutics market.

The inadequacy of skilled oncologists is acting as a constraint on the growth of the small-cell lung cancer therapeutics market during the projected period. The scarcity of proficient oncologists poses a significant challenge for individuals dealing with small-cell lung cancer (SCLC). This shortage can result in delayed diagnosis and treatment, an elevated risk of complications, reduced demand for SCLC therapeutics, an increased likelihood of treatment errors, and diminished patient satisfaction.For example, in 2022, as reported by the American Society of Clinical Oncology (ASCO), a professional health organization, there is a projected shortage of 2,393 oncologists anticipated by the year 2025. Consequently, the deficiency of skilled oncologists is impeding the growth of the small-cell lung cancer therapeutics market.

The prominent companies operating in the realm of small-cell lung cancer therapeutics are dedicated to pioneering new drugs as a means to gain a competitive edge and bolster their market position. An illustrative case is that of G1 Therapeutics Inc., a US-based oncology company, which, in February 2021, introduced COSELA (trilaciclib) for small-cell lung cancer therapeutics. This groundbreaking medication received approval from the Food and Drug Administration (FDA), a US-based government agency.COSELA is an injectable solution designed to mitigate the risk of chemotherapy-induced myelosuppression in adult patients undergoing a platinum/etoposide- or topotecan-based regimen for advanced small-cell lung cancer (ES-SCLC). Remarkably, it stands as the first and only medicine developed to safeguard the bone marrow (offering myeloprotection) when administered prior to chemotherapy treatment. This pioneering approach underscores how innovative drug development is transforming the landscape of small-cell lung cancer therapeutics.

In April 2021, Agilent Technologies Inc., a United States-based company renowned for its provision of instruments, software, services, and laboratory consumables, executed the acquisition of Resolution Bioscience. The financial details of this acquisition remain undisclosed. This strategic move by Agilent Technologies is driven by the objective of expanding its capabilities in the realm of next-generation sequencing (NGS)-based cancer diagnostics. It positions the company to leverage state-of-the-art technology, ensuring it is well-prepared to meet the evolving requirements of the rapidly growing precision medicine industry, particularly in the domain of precision oncology solutions.Resolution Bioscience, a United States-based biotechnology firm, specializes in the development of liquid biopsy assays tailored for cancer diagnosis and the monitoring of treatment progress, with a primary focus on small-cell lung cancer.

Major players in the small cell lung cancer therapeutics market are Pfizer Inc., Johnson and Johnson Private Limited, F. Hoffmann-La Roche AG, AbbVie Inc, Bayer AG, Janssen Pharmaceuticals, Novartis AG, Merck and Co. Inc., Sanofi S.A, Bristol-Myers Squibb Company, Astrazeneca plc, GSK plc, Medtronic plc, Eli Lilly and Company, Gilead Sciences Inc, Boehringer Ingelheim International GmbH, Otsuka Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals, Mylan N.V., Astellas Pharma Inc., Daiichi Sankyo Company Ltd., Vertex Pharmaceuticals, Aurobindo Pharma Limited, Kyowa Kirin Co. Ltd.

North America was the largest region in the small cell Lung cancer therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in small cell lung cancer therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the small cell lung cancer therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary drugs utilized in small-cell lung cancer therapeutics consist of atezolizumab, topotecan, lurbinectedin, durvalumab, methotrexate, and pembrolizumab. Atezolizumab falls into the category of immunotherapy drugs, specifically an immune checkpoint inhibitor. The treatment approaches encompass chemotherapy, targeted therapy, and various others. These treatments are administered through different routes, including oral, parenteral, and others, with end-users encompassing hospitals, cancer therapy centers, and various other healthcare facilities.

This report provides small cell lung cancer therapeutics market statistics, including small cell lung cancer therapeutics industry global market size, regional shares, competitors with a small cell lung cancer therapeutics market share, detailed small cell lung cancer therapeutics market segments, market trends and opportunities and any further data you may need to thrive in the small cell lung cancer therapeutics industry. This small cell lung cancer therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The small cell lung cancer therapeutics market includes revenues earned by entities by providing diagnosis services, palliative care and radiation therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The small cell lung cancer therapeutics market consists of sales of rova-T, cisplatin and carboplatin. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.